308 related articles for article (PubMed ID: 10352881)
1. Orthotopic models are necessary to predict therapy of transplantable tumors in mice.
Killion JJ; Radinsky R; Fidler IJ
Cancer Metastasis Rev; 1998-1999; 17(3):279-84. PubMed ID: 10352881
[TBL] [Abstract][Full Text] [Related]
2. What is the optimal rodent model for anti-tumor drug testing?
Kerbel RS
Cancer Metastasis Rev; 1998-1999; 17(3):301-4. PubMed ID: 10352884
[TBL] [Abstract][Full Text] [Related]
3. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
4. Experimental design for the evaluation of the antitumor action of cytokines.
Ciolli V; Sestili P; Brigato M; Gabriele L; Varano F; Locardi C; Belardelli F
Ann Ist Super Sanita; 1990; 26(3-4):441-51. PubMed ID: 2091505
[TBL] [Abstract][Full Text] [Related]
5. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.
Hoffman RM
Invest New Drugs; 1999; 17(4):343-59. PubMed ID: 10759402
[TBL] [Abstract][Full Text] [Related]
6. Medicine. Building better mouse models for studying cancer.
Marx J
Science; 2003 Mar; 299(5615):1972-5. PubMed ID: 12663895
[No Abstract] [Full Text] [Related]
7. Mouse models in oncogenesis and cancer therapy.
Céspedes MV; Casanova I; Parreño M; Mangues R
Clin Transl Oncol; 2006 May; 8(5):318-29. PubMed ID: 16760006
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic strategies for neoplasia.
Talmadge JE
Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
[No Abstract] [Full Text] [Related]
9. Trials, tribulations, and trends in tumor modeling in mice.
Schuh JC
Toxicol Pathol; 2004; 32 Suppl 1():53-66. PubMed ID: 15209404
[TBL] [Abstract][Full Text] [Related]
10. [New approaches in experimental cancerology: in search of therapeutic models].
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Pierré A; Hickman J
Bull Cancer; 2001 Jan; 88(1):75-84. PubMed ID: 11182656
[No Abstract] [Full Text] [Related]
11. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of biological response modifiers against transplantable mouse tumors of spontaneous origin. I. Characterization of biological properties of tumor lines and preliminary data on response to cytostatic drugs and biomodulators.
Fiszer-Maliszewska L; Mordarski M; Madej JA
Arch Immunol Ther Exp (Warsz); 1993; 41(1):1-9. PubMed ID: 8239902
[TBL] [Abstract][Full Text] [Related]
13. Assessing growth and response to therapy in murine tumor models.
Reynolds CP; Sun BC; DeClerck YA; Moats RA
Methods Mol Med; 2005; 111():335-50. PubMed ID: 15911989
[TBL] [Abstract][Full Text] [Related]
14. The use of the orthotopic model to validate antivascular therapies for cancer.
Loi M; Di Paolo D; Becherini P; Zorzoli A; Perri P; Carosio R; Cilli M; Ribatti D; Brignole C; Pagnan G; Ponzoni M; Pastorino F
Int J Dev Biol; 2011; 55(4-5):547-55. PubMed ID: 21858775
[TBL] [Abstract][Full Text] [Related]
15. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer).
Rosenberg MP; Bortner D
Cancer Metastasis Rev; 1998-1999; 17(3):295-9. PubMed ID: 10352883
[No Abstract] [Full Text] [Related]
16. Clinical studies on a new screening assay for anticancer agents using nude mice and isotopic evaluation.
Noso Y; Niimi K; Nishiyama M; Hirabayashi N; Toge T; Niimoto M; Hattori T
Cancer Res; 1987 Dec; 47(23):6418-22. PubMed ID: 3677085
[TBL] [Abstract][Full Text] [Related]
17. [The use of induced and spontaneous animal neoplasms in the experimental therapy of tumors].
Anikin IV; Pliss GB; Vlasov NN
Vopr Onkol; 1993; 39(4-6):161-8. PubMed ID: 7975390
[No Abstract] [Full Text] [Related]
18. Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes.
Lamb JR; Friend SH
Nat Med; 1997 Sep; 3(9):962-3. PubMed ID: 9288720
[No Abstract] [Full Text] [Related]
19. Strategy for developing transgenic assays for screening antineoplastic drugs that affect tubulin polymerization.
Porter GM; Armstrong L; Nielsen LL
Lab Anim Sci; 1995 Apr; 45(2):145-50. PubMed ID: 7603014
[TBL] [Abstract][Full Text] [Related]
20. [Carcinostatic action of synthetic polymers on transplantable tumors].
Korosteleva TA; Movsesian KA; Meiia NV; Nesterova VI; Sorokin AIa
Vopr Onkol; 1982; 28(6):39-41. PubMed ID: 7090295
[No Abstract] [Full Text] [Related]
[Next] [New Search]
